Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seaport Therapeutics, Inc. - Common Stock (NQ:SPTX)

18.50 +0.59 (+3.29%)
Delayed Quote Updated: 10:24 AM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seaport Therapeutics, Inc. - Common Stock

News headline image
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
From PureTech Health plc
Via Business Wire
News headline image
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics to Participate in September Investor Conferences
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
From PureTech Health plc
Via Business Wire
News headline image
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
From PureTech Health plc
Via Business Wire
News headline image
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
From Seaport Therapeutics, Inc.
Via Business Wire
News headline image
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
From Seaport Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.